...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Two big thank you’s

jonzobot - That was a Fair Value not a Fair Market Value that they used to have in the FAQ's. It was just one they generated for their financial statements, etc. and warned against using it for other puposes. That wasn't the Fair Market Value that CRA is concerned with. Maybe they removed it from the FAQ's because people kept trying to use it for other purposes.

I can look at the financials and tell you that it was probably $0.59 on both April 30 and July 31 this year. It is just something they choose and can be balanced off in the financials by Contributed Surplus and Shareholder deficiency to make it balance. You have no way to know what all went into their determination and how representative it is to their estimation of value but also might be not bad. They just warn to not use it.

Share
New Message
Please login to post a reply